SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

1/10/23 12:48:26 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VOR alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 VOR BIOPHARMA INC COMMON STOCK Cusip #929033108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #929033108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,970,488 Item 6: 0 Item 7: 7,970,511 Item 8: 0 Item 9: 7,970,511 Item 11: 12.141% Item 12: HC Cusip #929033108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,970,511 Item 8: 0 Item 9: 7,970,511 Item 11: 12.141% Item 12: IN Item 1(a). Name of Issuer: VOR BIOPHARMA INC Item 1(b). Address of Issuer's Principal Executive Offices: 100 CAMBRIDGEPARK DRIVE, SUITE 101 CAMBRIDGE, MA 02140 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 929033108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,970,511 (b) Percent of Class: 12.141% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,970,511 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of VOR BIOPHARMA INC. No one other person's interest in the COMMON STOCK of VOR BIOPHARMA INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on January 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of VOR BIOPHARMA INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $VOR alert in real time by email

Recent Analyst Ratings for

$VOR

Date	Price Target	Rating	Analyst
9/24/2025	$55.00	Hold → Buy	Stifel
6/30/2025	$3.00	Neutral → Buy	H.C. Wainwright
7/26/2022	$18.00	Outperform	Wedbush
4/27/2022	$6.00	Neutral	Goldman
12/17/2021	$26.00	Buy	HC Wainwright & Co.
12/3/2021	$38.00	Outperform	Robert W. Baird
12/3/2021	$38.00	Outperform	Baird
12/2/2021	$30.00	Outperform	Oppenheimer

More analyst ratings

SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

1/10/23 12:48:26 PM ET

$VOR

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VOR alert in real time by email

Recent Analyst Ratings for

$VOR

Date	Price Target	Rating	Analyst
9/24/2025	$55.00	Hold → Buy	Stifel
6/30/2025	$3.00	Neutral → Buy	H.C. Wainwright
7/26/2022	$18.00	Outperform	Wedbush
4/27/2022	$6.00	Neutral	Goldman
12/17/2021	$26.00	Buy	HC Wainwright & Co.
12/3/2021	$38.00	Outperform	Robert W. Baird
12/3/2021	$38.00	Outperform	Baird
12/2/2021	$30.00	Outperform	Oppenheimer

More analyst ratings

SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$VOR

SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$VOR

$VOR
SEC Filings

SEC Form SCHEDULE 13G filed by Vor Biopharma Inc.

SEC Form S-8 filed by Vor Biopharma Inc.

SEC Form S-3 filed by Vor Biopharma Inc.

$VOR
Insider Trading

SEC Form 4 filed by Director Ra Capital Management, L.P.

Large owner Reprogrammed Interchange Llc sold $688,853 worth of shares (447,278 units at $1.54), decreasing direct ownership by 1% to 32,781,209 units (SEC Form 4)

Large owner Reprogrammed Interchange Llc sold $1,703,971 worth of shares (984,805 units at $1.73), decreasing direct ownership by 3% to 33,228,487 units (SEC Form 4)

$VOR
Press Releases

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

$VOR
Insider Purchases

Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

$VOR
Analyst Ratings

Vor Biopharma upgraded by Stifel with a new price target

Vor Biopharma upgraded by H.C. Wainwright with a new price target

Wedbush initiated coverage on Vor Biopharma with a new price target

$VOR
Financials

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

$VOR
Leadership Updates

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

$VOR
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)